Skip to main content

Table 1 Percent cumulative incidences (with 95% confidence intervals in parentheses) of CRC at ages 30, 40, 50, 60 and 70 years by gender and genetic variant for both series for European path_MMR carriers separately and for all carriers irrespective of residence, and overall cumulative incidence at 25 years in the IMRC series

From: Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium

  

% cumulative incidences CRC (95% confidence intervals)

Sex

Gene

Continent

25 years

30 years

40 years

50 years

60 years

70 years

Male

MLH1

Europe IMRC

 

0.9 (0.4-1.8)

2.6 (1.2-5.2)

8.1 (5.0-14)

21 (15-29)

36 (27-48)

Europe PLSD

 

2.7 (1.0-7.0)

14.2 (10.2-19.6)

30.3 (25.0-36.6)

44.3 (37.9-51.2)

49.2 (42.0-56.8)

All IMRC

0.7 (0.5-1.1)

1.5 (1.1-2.2)

5.8 (4.3-7.8)

15 (12-19)

27 (23-33)

40 (34-47)

All PLSD

 

3.5 (1.6-7.6)

14.8 (10.9-20.0)

32.1 (27.0-38.0)

45.1 (39.2-51.4)

51.9 (45.2-58.9)

MSH2

Europe IMRC

 

0.7 (0.4-1.5)

2.2 (1.1-4.2)

6.7 (4.1-11)

16 (12-22)

28 (21-38)

Europe PLSD

 

2.7 (0.9-8.1)

8.9 (5.3-14.6)

19.1 (13.9-25.9)

34.1 (26.8-42.8)

46.4 (37.1-56.7)

All IMRC

0.6 (0.4-0.8)

1.2 (0.9-1.8)

4.8 (3.6-6.5)

13 (10-16)

23 (19-28)

34 (28-40)

All PLSD

 

3.7 (1.6-8.8)

10.4 (6.8-15.9)

21.3 (16.3-27.4)

37.3 (30.8-44.6)

49.6 (41.5-58.4)

MSH6

Europe IMRC

 

0.4 (0.1-1.3)

1.2 (0.4-3.8)

3.6 (1.4-9.7)

8.1 (4.1-17)

14 (7.8-24)

Europe PLSD

 

3.1 (0.4-20.1)

4.6 (1.1-18.5)

5.9 (1.8-18.6)

11.5 (5.5-23.5)

11.5 (5.5-23.5)

 

All IMRC

0.2 (0.1-0.4)

0.4 (0.2-0.9)

1.6 (0.9-3.2)

4.8 (3.0-8.7)

9.9 (7.0-16)

16 (12-24)

All PLSD

 

2.8

6.0

7.1

11.8

13.4

  

(0.4-18.3)

(1.9-18.1)

(2.6-18.7)

(5.9-22.9)

(7.0-24.9)

PMS2

Europe IMRC

 

0.1 (0.1-0.1)

0.3 (0.3-0.3)

1.0 (0.9-1.1)

3.5 (2.8-4.1)

7.6 (5.7-9.7)

Europe PLSD

 

0 (-)

0 (-)

0 (-)

12.1 (3.2-40.3)

12.1 (3.2-40.3)

All IMRC

0.0 (0.0-0.0)

0.1 (0.1-0.1)

0.3 (0.3-0.3)

1.1 (1.0-1.1)

3.3 (3.0-3.6)

7.1 (6.3-8.1)

All PLSD

 

0 (-)

0 (-)

0 (-)

10.7 (2.8-36.5)

10.7 (2.8-36.5)

Female

MLH1

Europe IMRC

 

0.4 (0.2-0.9)

1.3 (0.6-2.9)

4.7 (2.6-8.2)

12 (8.4-18)

22 (15-32)

Europe PLSD

 

0 (-)

8.5 (5.7-12.7)

17.8 (13.8-22.8)

29.9 (24.7-35.9)

41.0 (34.7-48.0)

All IMRC

0.4 (0.3-0.7)

0.8 (0.5-1.2)

3.1 (2.2-4.5)

8.6 (6.6-12)

17 (14-21)

27 (22-33)

All PLSD

 

0 (-)

9.3 (6.5-13.2)

18.2 (14.5-22.9)

29.9 (25.1-35.4)

41.3 (35.4-47.8)

MSH2

Europe IMRC

 

0.4 (0.2-1.0)

1.5 (0.7-3.3)

4.7 (2.6-8.9)

10 (6.7-17)

17 (11-27)

Europe PLSD

 

2.3 (0.7-6.9)

7.2 (4.1-12.4)

15.3 (10.8-21.4)

23.3 (17.8-30.1)

38.6 (31.4-46.9)

 

All IMRC

0.4 (0.3-0.7)

0.8 (0.6-1.3)

3.3 (2.3-5.0)

8.7 (6.5-12)

15 (12-20)

23 (19-29)

All PLSD

 

1.8 (0.6-5.4)

7.1 (4.3-11.6)

15.4 (11.4-20.6)

23.4 (18.6-29.1)

38.7 (32.5-45.6)

MSH6

Europe IMRC

 

0.1 (0.0-0.2)

0.2 (0.1-0.7)

0.8 (0.3-2.3)

2.5 (1.3-5.5)

5.6 (2.8-11)

 

Europe PLSD

 

0 (-)

0 (-)

3.1 (1.0-9.5)

8.2 (4.4-15.3)

14.5 (8.7-23.5)

All IMRC

0.0 (0.0-0.1)

0.1 (0.0-0.2)

0.3 (0.1-1.0)

1.0 (0.6-3.0)

3.4 (2.4-6.4)

8.1 (5.5-13)

All PLSD

 

0 (-)

1.2 (0.2-8.2)

4.0 (1.5-10.4)

8.4 (4.6-15.2)

16.8 (10.8-25.5)

PMS2

Europe IMRC

 

0.1 (0.1-0.1)

0.2 (0.2-0.2)

0.9 (0.8-0.9)

2.6 (2.2-3.0)

5.3 (4.2-6.6)

Europe PLSD

 

0 (-)

0 (-)

0 (-)

0 (-)

3.4 (0.5-21.7)

All IMRC

0.0 (0.0-0.0)

0.1 (0.1-0.1)

0.3 (0.3-0.3)

1.0 (1.0-1.0)

2.7 (2.5-2.9)

5.6 (5.0-6.2)

All PLSD

 

0 (-)

0 (-)

0 (-)

0 (-)

7.9 (1.9-29.3)

Back to article page

Hereditary Cancer in Clinical Practice

ISSN: 1897-4287